Skip to main content
OpenTrials
Completed

NCT Number: NCT01556126

Clinical Performance of CRE8 Drug Eluting Stent in All Comer Population

The aim of this study is to evaluate safety and efficacy performances of CRE8 Drug Eluting Stent, in patients comparable to the everyday's clinical practice population, with a specific focus on diabetics, that will be part of a pre-specified study subgroup.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medizinische Universität Innsbruck, Innsbruck, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years;
  • Patients with symptoms of stable angina or documented silent ischemia;
  • Patient with coronary artery disease ranging between 0 and 22 according to the Syntax score;
  • Patients with acute coronary syndrome, including unstable angina, NSTEMI and STEMI;
  • Patient is eligible for percutaneous coronary intervention (PCI) and is an acceptable candidate for surgical revascularization (CABG);
  • Left ventricular ejection fraction > 30%;
  • Target de-novo lesions with diameter stenosis > 50% (including total occlusion);
  • Target lesion located in a target vessel with a diameter ranging from 2.5 to 4.0 mm;
  • Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee of the respective clinical site.

Exclusion criteria

  • Female with childbearing potential or lactating;
  • Known allergies to antiplatelets, anticoagulants, contrast media, sirolimus or cobalt chromium;
  • Acute or chronic renal dysfunction (defined as creatinine greater than 2.5 mg/dl or on dialysis);
  • Thrombocytopenia (platelet count less than 100,000/mm³) or hypercoagulable disorder;
  • Known significant gastro-intestinal or urinary bleeding within the past 6 months;
  • Patient refusing blood transfusion;
  • Patient currently under immunosuppressant therapy;
  • Patient with planned surgery within 6 months from the index procedure unless dual antiplatelet therapy is maintained throughout the peri-surgical period;
  • Co-morbidities that could interfere with completion of study procedures, or life expectancy less than 1 year;
  • Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study;
  • Patient underwent target vessel revascularization with a DES within 3 months prior to the index procedure;
  • Target lesion is located or supplied by an arterial or venous bypass graft.

Treatment and study plan

Amphilimus Eluting Stent (CRE8)

Device

Sirolimus formulated coronary eluting stent

Other names: CRE8

Primary outcomes

  1. Clinical composite endpoint: Cardiac death/Target vessel MI/Clinically indicated TLR

    Time frame: 6 months

Secondary outcomes

  1. Clinical composite endpoints: - Cardiac death/Target vessel MI/Clinically indicated TLR - All death/All MI/All Repeat Revascularization

    Time frame: At 30 days, 1 year and yearly up to 5 years

  2. Stent thrombosis

    Time frame: within 24 hours, 1 month, 6 months, 1 year and yearly up to 5 years

  3. Angiographic in-stent and in-segment endpoints (in the first 100 patients included in the pre-specified diabetic subgroup).

    Time frame: At 6 months

    reference vessel diameter; minimal lumen diameter; % diameter stenosis; binary restenosis; late lumen loss

Sponsors and collaborators

Lead sponsor

CID - Carbostent & Implantable Devices

Industry

Registry information

Official study title

Prove ART (Abluminal Reservoir Technology) Clinical Benefit in Alla Comers Patients

Acronym: PARTICIPATE

Important dates

Study start
2012
Primary completion
2014
Study completion
2018
First posted
Mar 16, 2012
Registry last updated
Jul 20, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.